Neurological Institute, Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio.
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.
Oper Neurosurg (Hagerstown). 2020 Nov 16;19(6):641-650. doi: 10.1093/ons/opaa206.
Surgical options for patients with thalamic brain tumors are limited. Traditional surgical resection is associated with a high degree of morbidity and mortality. Laser interstitial thermal therapy (LITT) utilizes a stereotactically placed laser probe to induce thermal damage to tumor tissue. LITT provides a surgical cytoreduction option for this challenging patient population. We present our experience treating thalamic brain tumors with LITT.
To describe our experience and outcomes using LITT on patients with thalamic tumors.
We analyzed 13 consecutive patients treated with LITT for thalamic tumors from 2012 to 2017. Radiographic, clinical characteristics, and outcome data were collected via review of electronic medical records.
Thirteen patients with thalamic tumors were treated with LITT. Most had high-grade gliomas, including glioblastoma (n = 9) and anaplastic astrocytoma (n = 2). The average tumor volume was 12.0 cc and shrank by 42.9% at 3 mo. The average hospital stay was 3.0 d. Median ablation coverage as calculated by thermal damage threshold (TDT) lines was 98% and 95% for yellow (>43°C for >2 min) or blue (>10 min), respectively. Median disease-specific progression-free survival calculated for 8 patients in our cohort was 6.1 mo (range: 1.1-15.1 mo). There were 6 patients with perioperative morbidity and 2 perioperative deaths because of intracerebral hematoma.
LITT is a feasible treatment for patients with thalamic tumors. LITT offers a cytoreduction option in this challenging population. Patient selection is key. Close attention should be paid to lesion size to minimize morbidity. More studies comparing treatment modalities of thalamic tumors need to be performed.
对于丘脑脑肿瘤患者,手术选择有限。传统的手术切除与高发病率和死亡率相关。激光间质热疗(LITT)利用立体定向放置的激光探头诱导肿瘤组织热损伤。LITT 为这一具有挑战性的患者群体提供了一种手术细胞减少的选择。我们介绍了使用 LITT 治疗丘脑脑肿瘤的经验。
描述我们使用 LITT 治疗丘脑肿瘤患者的经验和结果。
我们分析了 2012 年至 2017 年期间接受 LITT 治疗的 13 例丘脑肿瘤患者。通过电子病历回顾收集影像学、临床特征和结果数据。
13 例丘脑肿瘤患者接受了 LITT 治疗。大多数患者患有高级别胶质瘤,包括胶质母细胞瘤(n=9)和间变性星形细胞瘤(n=2)。平均肿瘤体积为 12.0cc,3 个月时缩小了 42.9%。平均住院时间为 3.0 天。按热损伤阈值(TDT)线计算的平均消融覆盖率分别为黄色(>43°C 持续>2 分钟)或蓝色(>10 分钟)的 98%和 95%。在我们的队列中,8 例患者的疾病特异性无进展生存中位数为 6.1 个月(范围:1.1-15.1 个月)。有 6 例患者发生围手术期并发症,2 例围手术期死亡是由于颅内血肿。
LITT 是治疗丘脑肿瘤患者的一种可行方法。LITT 为这一具有挑战性的人群提供了一种细胞减少的选择。患者选择是关键。应密切注意病变大小,以最大限度地降低发病率。需要进行更多比较丘脑肿瘤治疗方式的研究。